[en] BACKGROUND: Deep phenotyping and longitudinal assessment of predementia at-risk states of Alzheimer's disease (AD) are required to define populations and outcomes for dementia prevention trials. Subjective cognitive decline (SCD) is a pre-mild cognitive impairment (pre-MCI) at-risk state of dementia, which emerges as a highly promising target for AD prevention.
METHODS: The German Center for Neurodegenerative Diseases (DZNE) is conducting the multicenter DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE), which focuses on the characterization of SCD in patients recruited from memory clinics. In addition, individuals with amnestic MCI, mild Alzheimer's dementia patients, first-degree relatives of patients with Alzheimer's dementia, and cognitively unimpaired control subjects are studied. The total number of subjects to be enrolled is 1000. Participants receive extensive clinical and neuropsychological assessments, magnetic resonance imaging, positron emission tomography, and biomaterial collection is perfomed. In this publication, we report cognitive and clinical data as well as apolipoprotein E (APOE) genotype and cerebrospinal fluid (CSF) biomarker results of the first 394 baseline data sets.
RESULTS: In comparison with the control group, patients with SCD showed slightly poorer performance on cognitive and functional measures (Alzheimer's Disease Assessment Scale-cognitive part, Clinical Dementia Rating, Functional Activities Questionnaire), with all mean scores in a range which would be considered unimpaired. APOE4 genotype was enriched in the SCD group in comparison to what would be expected in the population and the frequency was significantly higher in comparison to the control group. CSF Aβ42 was lower in the SCD group in comparison to the control group at a statistical trend with age as a covariate. There were no group differences in Tau or pTau concentrations between the SCD and the control groups. The differences in all measures between the MCI group and the AD group were as expected.
CONCLUSIONS: The initial baseline data for DELCODE support the approach of using SCD in patients recruited through memory clinics as an enrichment strategy for late-stage preclinical AD. This is indicated by slightly lower performance in a range of measures in SCD in comparison to the control subjects as well as by enriched APOE4 frequency and lower CSF Aβ42 concentration.
TRIAL REGISTRATION: German Clinical Trials Register DRKS00007966 . Registered 4 May 2015.
Disciplines :
Neurology
Author, co-author :
Jessen, Frank; German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Straße 27, 53127, Bonn, Germany. frank.jessen@uk-koeln.de ; Department of Psychiatry, Medical Faculty, University of Cologne, Kerpener Straße 62, 50924, Cologne, Germany. frank.jessen@uk-koeln.de
Spottke, Annika; German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Straße 27, 53127, Bonn, Germany ; Department of Neurology, University of Bonn, Sigmund-Freud-Straße 25, 53127, Bonn, Germany
Boecker, Henning; German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Straße 27, 53127, Bonn, Germany ; Department of Radiology, University of Bonn, Sigmund-Freud-Straße 25, 53127, Bonn, Germany
Brosseron, Frederic; German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Straße 27, 53127, Bonn, Germany
Buerger, Katharina; German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Straße 17, 81377, Munich, Germany ; Institute for Stroke and Dementia Research, Klinikum der Universität München, Feodor-Lynen-Straße 17, 81377, Munich, Germany
Catak, Cihan; Institute for Stroke and Dementia Research, Klinikum der Universität München, Feodor-Lynen-Straße 17, 81377, Munich, Germany
Fliessbach, Klaus; German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Straße 27, 53127, Bonn, Germany ; Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Sigmund-Freud-Straße 25, 53127, Bonn, Germany ; Department of Psychiatry and Psychotherapy, University of Bonn, Sigmund-Freud-Straße 25, 53127, Bonn, Germany
Franke, Christiana; Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117, Berlin, Germany
Fuentes, Manuel; Department of Psychiatry and Psychotherapy, Charité, Hindenburgdamm 30, 12203, Berlin, Germany
HENEKA, Michael ; German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Straße 27, 53127, Bonn, Germany ; Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Sigmund-Freud-Straße 25, 53127, Bonn, Germany
Janowitz, Daniel; Institute for Stroke and Dementia Research, Klinikum der Universität München, Feodor-Lynen-Straße 17, 81377, Munich, Germany
Kilimann, Ingo; German Center for Neurodegenerative Diseases (DZNE), Gehlsheimer Straße 20, 18147, Rostock, Germany ; Department of Psychosomatic Medicine, University of Rostock, Gehlsheimer Straße 20, 18147, Rostock, Germany
Laske, Christoph; German Center for Neurodegenerative Diseases (DZNE), Otfried-Müller-Straße 23, 72076 Tübingen, Germany ; Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Calwerstraße 14, 72076 Tübingen, Germany
Menne, Felix; Department of Psychiatry and Psychotherapy, Charité, Hindenburgdamm 30, 12203, Berlin, Germany
Nestor, Peter; German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, 39120, Magdeburg, Germany
Peters, Oliver; Department of Psychiatry and Psychotherapy, Charité, Hindenburgdamm 30, 12203, Berlin, Germany ; German Center for Neurodegenerative Diseases (DZNE), Charitéplatz 1, 10117 Berlin, Germany
Priller, Josef; Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117, Berlin, Germany ; German Center for Neurodegenerative Diseases (DZNE), Charitéplatz 1, 10117 Berlin, Germany
Pross, Verena; German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Straße 27, 53127, Bonn, Germany
Ramirez, Alfredo; Department of Psychiatry, Medical Faculty, University of Cologne, Kerpener Straße 62, 50924, Cologne, Germany ; Department of Psychiatry and Psychotherapy, University of Bonn, Sigmund-Freud-Straße 25, 53127, Bonn, Germany ; Institute of Human Genetics, University of Bonn, Sigmund-Freud-Straße 25, 53127, Bonn, Germany
Schneider, Anja; German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Straße 27, 53127, Bonn, Germany ; Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Sigmund-Freud-Straße 25, 53127, Bonn, Germany
Speck, Oliver; Department of Biomedical Magnetic Resonance, Otto-von-Guericke University Magdeburg, Leipziger Straße 44, 39120, Magdeburg, Germany
Spruth, Eike Jakob; Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117, Berlin, Germany
Teipel, Stefan; German Center for Neurodegenerative Diseases (DZNE), Gehlsheimer Straße 20, 18147, Rostock, Germany ; Department of Psychosomatic Medicine, University of Rostock, Gehlsheimer Straße 20, 18147, Rostock, Germany
Vukovich, Ruth; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Von-Siebold-Straße 5, 37075, Goettingen, Germany
Westerteicher, Christine; German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Straße 27, 53127, Bonn, Germany ; Department of Psychiatry and Psychotherapy, University of Bonn, Sigmund-Freud-Straße 25, 53127, Bonn, Germany
Wiltfang, Jens; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Von-Siebold-Straße 5, 37075, Goettingen, Germany ; German Center for Neurodegenerative Diseases (DZNE), 37075 Goettingen, Von-Siebold-Str. 3a, Germany ; iBiMED, Medical Sciences Department, University of Aveiro, Aveiro, Portugal
Wolfsgruber, Steffen; German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Straße 27, 53127, Bonn, Germany ; Department of Psychiatry and Psychotherapy, University of Bonn, Sigmund-Freud-Straße 25, 53127, Bonn, Germany
Wagner, Michael; German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Straße 27, 53127, Bonn, Germany ; Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Sigmund-Freud-Straße 25, 53127, Bonn, Germany ; Department of Psychiatry and Psychotherapy, University of Bonn, Sigmund-Freud-Straße 25, 53127, Bonn, Germany
Düzel, Emrah; German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, 39120, Magdeburg, Germany
Deutsches Zentrum für Neurodegenerative Erkrankungen
Funding text :
The study was funded by the German Center for Neurodegenerative Diseases (Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)), reference number BN012.
Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15:455-532.
Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013;9:438-44.
Reiman EM, Langbaum JB, Tariot PN, Lopera F, Bateman RJ, Morris JC, et al. CAP - advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol. 2016;12:56-61.
Koppara A, Frommann I, Polcher A, Parra MA, Maier W, Jessen F, et al. Feature binding deficits in subjective cognitive decline and in mild cognitive impairment. J Alzheimers Dis. 2015;48 Suppl 1:161-70.
Smart CM, Krawitz A. The impact of subjective cognitive decline on Iowa Gambling Task performance. Neuropsychology. 2015;29:971-87.
Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand. 2014;130:439-51.
Scheef L, Spottke A, Daerr M, Joe A, Striepens N, Kölsch H, Popp J, Daamen M, Gorris D, Heneka MT, Boecker H, Biersack HJ, Maier W, Schild HH, Wagner M, Jessen F. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology. 2012;79:1332-9.
Peter J, Scheef L, Abdulkadir A, Boecker H, Heneka M, Wagner M, et al. Gray matter atrophy pattern in elderly with subjective memory impairment. Alzheimers Dement. 2014;10:99-108.
van Harten AC, Visser PJ, Pijnenburg YA, Teunissen CE, Blankenstein MA, Scheltens P, et al. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement. 2013;9:481-7.
Sierra-Rio A, Balasa M, Olives J, Antonell A, Iranzo A, Castellví M, et al. Cerebrospinal fluid biomarkers predict clinical evolution in patients with subjective cognitive decline and mild cognitive impairment. Neurodegener Dis. 2016;16:69-76.
Wolfsgruber S, Polcher A, Koppara A, Kleineidam L, Frölich L, Peters O, et al. Cerebrospinal fluid biomarkers and clinical progression in patients with subjective cognitive decline and mild cognitive impairment. J Alzheimers Dis.2017;58:939-50.
Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014;10:844-52.
Molinuevo JL, Rabin LA, Amariglio R, Buckley R, Dubois B, Ellis KA, et al. Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 2017;13:296-311.
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-92.
Erk S, Spottke A, Meisen A, Wagner M, Walter H, Jessen F. Evidence of neuronal compensation during episodic memory in subjective memory impairment. Arch Gen Psychiatry. 2011;68:845-52.
Buckley RF, Villemagne VL, Masters CL, Ellis KA, Rowe CC, Johnson K, et al. A conceptualization of the utility of subjective cognitive decline in clinical trials of preclinical Alzheimer's disease. J Mol Neurosci. 2016;60:354-61.
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270-9.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-9.
Polcher A, Frommann I, Koppara A, Wolfsgruber S, Jessen F, Wagner M. Face-name associative recognition deficits in subjective cognitive decline and mild cognitive impairment. J Alzheimers Dis. 2017;56:1185-96.
Van Dam NT, Sano M, Mitsis EM, Grossman HT, Gu X, Park Y, et al. Functional neural correlates of attentional deficits in amnestic mild cognitive impairment. PLoS One. 2013;8:e54035.
Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3:154-65.
Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using beta-amyloid(1 42) and tau levels in CSF. Neurology. 1999;52:1555-62.
Duits FH, Teunissen CE, Bouwman FH, Visser P, Mattsson N, Zetterberg H, et al. The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean? Alzheimers Dement. 2014;10:713-23.
Davids M, Zöllner FG, Ruttorf M, Nees F, Flor H, Schumann G, et al. Fully-automated quality assurance in multi-center studies using MRI phantom measurements. Magn Reson Imaging. 2014;32:771-80.
Joshi A, Koeppe RA, Fessler JA. Reducing between scanner differences in multi-cente PET studies. Neuroimage. 2009;46:154-9.
Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-β PET with florbetaben (18 F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424-35.
Teng E, Becker BW, Woo E, Knopman DS, Cummings JL, Lu PH. Utility of the functional activities questionnaire for distinguishing mild cognitive impairment from very mild Alzheimer's disease. Alzheimer Dis Assoc Disord. 2010;24:348-53.
Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE∗4 a 'thrifty' allele? Ann Hum Genet. 1999;63:301-10.
